Abstract
Insulin-like growth factors (IGF) exhibit very potent mitogenic activity, promote cell survival, and have insulin-like functions essential for embryogenesis and postnatal growth physiology. Attention has recently focused on the role of IGF in neoplastic transformation, growth, and dissemination in several cancer types, including human breast cancer. Neoplastic cells are characterized by relative growth autonomy, a consequence of the constitutive expression of IGF and their receptors involved in autocrine loops. This chapter will focus on the molecular mechanisms underlying IGF action in tumourigenesis, in particular its chemoattractant activity and its relevance in tumour motility, both of which lead to invasion. Several of the IGF-induced cellular changes will be highlighted, such as cell polarizatiom, adhesion and detachment, as well as proteolysis induction. Finally, we will summarize the significance of IGF system components as prognostic markers in human breast cancer, and discuss the possible therapeutic considerations encompassed by these factors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Salmon W, Daughaday W. A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J. Lab. Clin. Med. 1957; 49:825–836
Froesch E, Burgi H, Ramseier E, Bally P, Labhart A. Antibody suppressible and non suppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J. Clin. Invest. 1963; 42:1816–1834
Dulak N, Temin H. Multiplication-stimulating activity for chicken embryo fibroblasts from rat livercell conditioned medium: A family of small polypeptides. J. Cell. Physiol. 1973; 81:161–170
Rinderknecht E, Humbel R. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J. Biol.Chem. 1978; 253:2769–2776
Rinderknecht E, Humbel R. Primary structure of human insulin-like growth factor-II. FEBS Lett 1978;89:283–286
Iwai M, Kobayashi M, Tamura K, Ishii Y, Yamada H, Niwa M. Direct identification of disulfide bond linkages in human insulin-like growth factor I (IGF-I) by chemical synthesis. J. Biochem. 1989; 106:949–951
Dull T, Gray A, Hayflick J, Ullrich A. Insulin-like growth factor-II precursor gene reorganization in relation toinsulin gene family. Nature 1984; 310:777–781
Sara V, Hall K. Insulin-like growth factors and their binding proteins. Physiol. Rev. 1990; 70:591–614
Gowan L, Hampton B, Hill D, Schlueter R, Perdue J. Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. Endocrinology 1991; 121:449–458
Perdue J, LeBon T, Kato J, Hampton B, Fujita-Yamaguchi Y. Binding specificities and transducing function of the different molecular weight forms of insulin-like growth factor-II (IGF-II) on IGF-I receptors. Endocrinology 1991; 129:3101–3108
Lund P, Moats-Staats B, Hynes M, Simmons J, Jansen M, D’Ercole A, Van Wyk J. Somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues. J. Biol. Chem. 1986; 261:14539–14544
Brown A, Graham D, Nissley S, Hill D, Strain A, Rechler M. Developmental regulation of insulin-like growth factor II mRNA in different rat tissues. J. Biol. Chem. 1986; 261:13144–13150
Rotwein P, Pollock K, Didier D, Krivi G. Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J. Biol. Chem. 1986; 261:4828–4832
Jansen M, Van Schail F, Van Tol H, Van den Brande J, Sussenbach J. Nucleotide sequences of cDNAs encoding precursors of human insulin-like growth factor II (IGF-II) and an IGF-II variant. FEBS Lett. 1985; 179:243–246
Cascieri M, Bayne M. “Identification of the domains of IGF-I which interact with the IGF receptors and binding proteins.” In Molecular and Cellular Biology of Insulin-like Growth Factors and their Receptors. D. LeRoith and M. Raizada Eds. New York: Plenum Press, 1989
De Vroede M, Rechler M, Nissley S, Joshi S, Thompson-Burke G, Katsoyanis P. Hybrid molecules containing the B-domain of insulin-like growth factor I are recognized by carrier proteins of the growth factor. Proc. Natl. Acad. Sci. U.S.A. 1985; 82:3010–3014
Bayne M, Applebaum J, Chicchi G, Hayes N, Green B, Cascieri M. Structural analogs of insulin-like growth factor-I with reduced affinity for serum binding proteins and the Type-2 insulin-like growth factor receptor. J. Biol. Chem. 1988; 263:6233–6237
Cascieri M, Chicchi G, Applebaum J, Hayes N, Green B, Bayne M. Mutants of insulin-like growth factor I with reduced affinity for Type I insulin-like growth factor receptor. Biochemistry 1988; 27:3229–3233
Bayne M, Applebaum J, Underwood D, Chicchi G, Green B, Hayes N, Cascieri M. The C-region of human insulin-like growth factor (IGF)I is required for high affinity binding to the type-1 IGF receptor. J. Biol. Chem. 1989; 264:11004–11008
Bayne M, Applebaum J, Chicchi G, Miller E, Cascieri M. The roles of tyrosine 24, 31 and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor. J. Biol. Chem. 1990; 265:15648–15652
Clemmons D, Dehoff M, Busby W, Bayne M, Cascieri M. Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4 and 5 by the IGFs and the IGF analogs. Endocrinology 1992; 131:890–895
Oh Y, Müller H, Lee D-D, Fielder P, Rosenfeld R. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 1993; 132:1337–1344
Cooke R, Harvey T, Campbell I. Solution structure of human insulin-like growth factor 1: A nuclear magnetic resonance and restrained molecular dynamics study. Biochemistry 1991; 30:5484–5491
Clemmons D, Cascieri M, Camacho-Hubner C, McCusker R, Bayne M. Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor binding proteins result in changes in bioactivity. J. Biol. Chem. 1990; 265:12210–12216
Mañes S, Kremer L, Albar JP, Mark C, Llopis R, Martínez-A. C. Functional epitope mapping of insulin-like growth factor-I by anti-IGF-I monoclonal antibodies. Endocrinology 1997; 138:905–915
Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997; 7:111–113
Jones JC, Clemmons DR. Insulin-like growth factors and their binding proteins:biological actions. Endocrine Reviews 1995; 16: 3–34
Yamanaka Y, Wilson E, Rosenfeld R, Oh Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J. Biol. Chem. 1997; 272:30729–30734
Zapf J, Waldvogel M, Froesch R. Binding of non-suppressible insulin-like activity to human serum: Evidence for a carrier protein. Arch. Biochem. Biophys. 1975; 168:638–645
Hall K, Takano K, Fryklund L, Sievertsson H. Somatomedins. Adv. Metab. Disord. 1975; 8:19–46
Cohen K, Nissley S. The serum half-life of somatomedin activity: Evidence for growth hormone dependence. Acta Endocrinol. 1976; 83:243–258
Furlanetto R. The somatomedin C binding protein: evidence for a heterologous subunit structure. J. Clin. Endocrinol. Metab. 1980; 54:223–228
Martin J, Baxter R. Insulin-like growth factor binding protein from human plasma: Purification and characterization. J. Biol. Chem. 1986; 261:8754–8760
Baxter R, Martin J. Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity-labeling. Proc. Natl. Acad. Sci. USA 1989; 86:6898–6902
Bar R, Boes M, Dake B, Sandra A, Bayne M, Cascieri M, Booth B. Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I. Endocrinology 1990; 127:3243–3245
Bach L, Rechler M. Insulin-like growth factor binding proteins. Diabetes Rev. 1995; 3:38–61
Pratt S, Pollak M. Insulin-like growth factor binding protein 3 (IGF-Bp3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem. Biophys. Res. Commun. 1994; 198:292–297
Ritvos O, Ranta T, Jalkanen J, Suikkari A, Voutilainen R, Bohn H, Rutanen E. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 1988;1122:2150–2157
Rutanen E, Pekonen F, Mäkinen T. Soluble 34 K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J. Clin. Endocrinol. Metab. 1988; 66:173–180
Elgin RG, Busby WH, Clemmons DR. An insulin-like growthfactor (IGF) binding protein enhances the biological response to IGF-I. Proc.Natl.Acad.Sci. USA 1987; 84:3254–3258
Blum W, Jenne E, Reppin F, Kietzmann K, Ranke M, Bierich J. Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989; 125:766–772
Clemmons D, Elgin R, Han V, Casella S, D’Ercole A, Van Wyk J. Cultured fibroblasts monolayers secrete a protein that modulates the binding of somatomedin C/indulin-like growth factor I. Mol. Endocrinol. 1986; 1:339–347
Clemmons DR, Jones JI, Busby WH, Wright G. Role of insulin-like growth factor binding proteins in modifying IGF actions. Ann. N.Y. Acad. Sci. 1993; 692:10–21
McCusker R, Camacho-Hubner C, Bayne M, Cascieri M, Clemmons D. Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells: The modulating effect of cell released IGF binding proteins. J. Cell. Physiol. 1990; 144:244–253
McCusker R, Busby W, Dehoff M, Camacho-Hubner C, Clemmons D. Insulin-like growth factor (IGF) binding to cell monolayer is directly modulated by the addition of IGF binding proteins. Endocrinology 1991; 129:939–949
Chen J, Shao Z, Sheikh M, Hussain A, LeRoith D, Roberts C, Fontana J. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J. Cell. Physiol. 1994; 158:69–78
Hodgson D. Free-ligand accelerated dissociation of insulin-like growth factor 1 (IGF-1) from the type I IGF receptor is reduced by insulin-like growth factor binding protein 3. Regul. Pept. 2000; 90:33–37
DeMellow J, Baxter R. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem. Biophys. Res. Commun. 1988; 156:199–204
Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin-D mediated hydrolysis of insulin-like growth factor binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab. 1995; 80:987–993
Fowlkes J, Thrailkill K, Serra D, Suzuki K, Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog. Growth Factor Res 1995; 6:255–263
Mañes S, Mira E, Barbacid M, Ciprés A, Fernández-Resa P, Buesa J, Mérida I, Aracil M, Márquez G, Mártinez-A. C. Identification of insulin-like growth factor binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem. 1997; 272:25706–25712
Claussen M, Kubler B, Wendland M, Neifer K, Schmidt B, Zapf J, Braulke T. Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D. Endocrinology 1997; 138:3797–3803
Long L, Navab R, Brodt P. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res 1998; 58:3243–3247
Emonard H, Remacle A, Noel A, Grimaud J-A, Stetler-Stevenson W, Foidart J-M. Tumour cell surface-associated binding site for the Mr 72,000 type IV collagenase. Cancer Res 1992; 52:5845–5848
Brooks P, Strömblad S, Sanders L, von Schalscha T, Aimes R, Stetler-Stevenson W, Quigley J, Cheresh D. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3 Cell 1996; 85:683–693
Mira E, Mañes S, Lacalle R, Marquez G, Martinez-A. C. IGF-I-triggered cell migration and invasion is mediated by the matrix metalloproteinase MMP-9. Endocrinology 1998; 140:1657–1664
Conover C, Clarkson J, Bale L. Factors regulating insulin-like growth factor-binding protein-3 binding, processing and potentiation of insulin-like growth factor action. Endocrinology 1996; 137:2286–2292
Gill Z, Perks C, Newcomb P, Holly J. Insulin-like growth factor-binding Protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J. Biol. Chem. 1997; 272:25602–25607
Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 1998; 47:283–293
Cohen P, Lamson G, Okajima T, Rosenfeld R. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol. Endocrinol. 1993;7:380–386
Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol. Endocrinol. 1995; 9:361–367
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377:646–649
Swisshelm K, Ryan K, Tsuchiya K, Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc. Natl. Acad. Sci. U.S.A. 1995; 92:4472–4476
Lammers R, Gray A, Schlessinger J, Ullrich A. Differential signaling potential of insulin-and IGF-1-receptor cytoplasmic domains. EMBO J. 1989; 1989:1369–1375
Flier J, Usher P, Moses A. Monoclonal antibody to the type insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: Clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1986; 83:664–668
Czech M. Signal transmission by the Insulin-like growth factors. Cell 1989; 59:235–238
Ullrich A, Gray A, Tam A, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5:2503–2512
Massagué J, Czech M. The subunit structures of two distinct receptors for insulin-like growth factor I and II and their relationship to the insulin receptor. J. Biol. Chem. 1982; 257:5038–5041
Kasuga M, Sasaki N, Kahn C, Nissley S, Rechler M. Antireceptor antibodies as probes of insulin-like growth factor receptor structure. J. Clin. Invest. 1983; 72:1459–1469
Jacobs S, Kull F, Earp H, Svoboda M, Van Wyk J, Cuatrecasas P. Somatomedin-C stimulates the phosphorylation of the β-subunit of its own receptor. J. Biol. Chem. 1983; 258:9581–9584
Rubin J, Shia M, Pilch P. Stimulation of tyrosine-specific phosphorylation in vitro by insulin-like growth factor I. Nature 1983; 305:438–440
Frattali A, Pessin J. Relationship between alpha subunit ligand occupancy abd beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J. Biol. Chem. 1993; 268:7393–7400
Kato H, Faria T, Stannard B, Roberts C, LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. J. Biol. Chem. 1993; 268:2655–2661
Kornfeld S. Structure and function of the mannose-6-phosphate/ insulin-like growth factor-II receptors. Annu. Rev. Biochem. 1992; 61:307–330
Morgan D, Edman J, Standring D, Fried V, Smith M, Roth R, Rutter W. Insulin-like growth factor-II receptor as a multifunctional binding protein. Nature 1987;329:301–307
Kiess W, Haskell J, Lee L, Greenstein L, Miller B, Aarons A, Rechler M, Nissley S. An antibody that blocks insulin-like growth factor (IGF) binding to the type II IGF receptor is neither an agonist nor an inhibitor of IGF-stimulated biologic responses in L6 myoblasts. J. Biol. Chem. 1987; 262:12745–12751
Lau M, Stewart C, Liu Z, Bhatt H, Rotwein P, Stewart C. Loss of the imprinted IGF2/cation-independent mannose-6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev. 1994; 8:2953–2963
Shier P, Watt V. Primary structure of a putative receptor for a ligand of the insulin family. J. Biol. Chem. 1989; 264:14605–14608
Zhang B, Roth R. The insulin receptor-related receptor. Tissue expression, ligand binding specificity, and signaling capabilities. J. Biol. Chem. 1992; 267:18320–18328
Stewart C, Rotwein P. Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol. Rev. 1996; 76:1005–1026
Leof E, Walker W, Van Wyk J, Pledger W. Epidermal growth factor (EGF) and somatomedin C regulate G1 progression in competent BALB/c 3T3 cells. Exp. Cell. Res. 1982; 141:107–115
Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis A, Baserga R. Simian virus 40 large tumour antigen is unable to transform mouse embryonic fibroblastslacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 1993:90:11217–11221
Palmiter R, Norstedt G, Gelinas R, Hammer R, Brinster R. Metallothionein-human GH fusion genes stimulate growth of mice. Science 1983; 222:809–814
Mathews L, Hammer R, Behringer R, D’Ercole A, Bell G, Brinster R, Palmifer R. Growth enhancement of transgenic mice expressing insulin-like growth factor-I. Endocrinology 1988; 123:2827–2833
DeChiara T, Efstratiadis A, Robertson E. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990; 345:78–80
DeChiara T, Robertson E, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64:849–859
Wang Z, Fung M, Barlow D, Wagner E. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 1994; 372:464–467
Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75:73–82
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-I) and type-1 IGF receptor (IgfIr). Cell 1993; 75:59–72
Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA. IGF-I is required for normal embryonic growth in mice. Genes & Development 1993; 7:2609–2617
Araki E, Lipes M, Patti M, Bruning J, Haag B, Johnson R, Kahn C. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372:186–190
Withers D, Gutierrez J, Towery H, Burks D, Ren J, Previs S, Zhang Y, Bernal D, Pons S, Shulman G, Bonner-Weir S, White M. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391:900–904
DeMellow SR, Galli C, Ciotti T, Calissano P. Induction of apoptosis in cerebellar granule neurons by low potassium: Inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. U.S.A. 1993; 90:10989–10993
Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994; 13:3286–3295
Hueber A, Zornig M, Lyon D, Suda T, Nagata S, Evan G. Requeriment for the CD95 receptor ligand pathway in c-Myc-induced apoptosis. Science 1997; 278:1305–1309
Jung Y, Miura M, Yuan J. Suppression of interleukin-1 beta-converting enzyme-mediated cell death by insulin-like growth factor. J. Biol. Chem. 1996; 271:5112–5117
Heck S, Lezoualc’h F, Engert S, Behl C. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor κB. J. Biol. Chem. 1999; 274:9828–9835
Kaliman P, Canicio J, Testar X, Palacin M, Zorzano A. Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-κB and inducible nitric-oxide synthase define a common myogenic signaling pathway. J. Biol. Chem. 1999; 274:17437–17444
Hsu D, Knudson P, Zapf A, Rolband G, Olefsky J. NPXY motif in the insulin-like growth factor-I receptor is required for efficient ligand-mediated receptor internalization and biological signalling. Endocrinology 1994; 134:744–750
White M, Kahn C. The insulin signalling system. J. Biol. Chem. 1994; 269:1–4
Lavan B, Lane W, Lienhard G. The 60 kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J. Biol. Chem. 1997; 272:11439–11443
Fantin V, Lavan B, Wang Q, Jenkins N, Gilbert D, Copeland N, Keller S, Lienhard G. Cloning, tissue expression, and chromosomal location of the mouse insulin receptor substrate 4 gene. Endocrinology 1999; 140:1329–1337
Kulkarni R, Bruning J, Daniels M, Ning J, Flier S, Hanahan D, Kahn C. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured β lines. J. Clin. Invest. 1999; 104:R69–R75
Withers D, Burks D, Towery H, Altamuro S, Flin C, White M. Irs-2 coordinates Igf-1 receptor-mediated b-cell development and peripheral insulin signalling. Nat. Genet. 1999; 23:32–40
Liu S, Wang Q, Lienhard G, Keller S. Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J. Biol. Chem. 1999; 274:18093–18099
Fantin V, Wang Q, Lienhard G, Keller S. Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. Am. J. Physiol. Endocrinol. Metab. 2000; 278:E127–E133
Uchida T, Myers M, White M. IRS-4 mediates activation of PKB/Akt during insulin stimulation without inhibition of apoptosis. Mol. Cell. Biol. 2000; 20:126–138
Petley T, Graff K, Jiang W, Yang H and Florini, J. Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm. Metab. Res. 1999; 31:70–76
Wang L, Myers M, Sun X, Aaronson S, White M. Common elements in interleukin 4 and insulin signaling pathways in factor-dependent hematopoietic cells. Science 1993; 261:1591–1594
Myers M, Grammer T, Wang L, Sun X, Pierce J, Blenis J, White M. Insulin receptor substrate-1 mediates phosphatidylinositol 3’-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J. Biol. Chem. 1994; 269:28783–28789
Argetsinger L, Hsu G, Myers M, Billestrup N, White M, Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosine phosphorylation of insulin receptor substrate-1. J. Biol. Chem. 1995; 270:14685–14692
Ihle J. Cytokine receptor signalling. Nature 1995; 377:591–594
Vuori K, Ruoslahti E. Association of insulin receptor substrate-1 with integrins. Science 1994; 266:1576–1578
Kowalski-Chauvel A, Pradayrol L, Vaysse N, Seva C. Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate-1 and its association with Grb2 and the phosphatidylinositol 3-kinase. J. Biol. Chem. 1996; 271:26356–26361
Benz C. Transcription factors and breast cancer. Endocrine-Related Cancer 1998; 5:271–282
Surmacz E, Guvakova, MA, Nolan, MK, Nicosia, RF and Sciacca, L. Type I insulin-like growth factor receptor function in breast cancer. Breast. Cancer Res. Treat. 1998; 47:255–267
Stewart A, Johnson M, May F, Westley B. Role of insulin-ike growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 1990; 265:21172–21178
Lee A, Jackson J, Gooch J, Hilsenbeck S, Coronado-Heinsohn E, Osborne C, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 1999; 5:787–796
Westley B, Clayton, SJ, Daws, MR, Molloy, CA and May, FE. Interactions between the oestrogen and insulin-like growth factor signaling pathways in the control of breast epithelial cell proliferation. Biochem. Soc. Symp. 1998; 63
Mathieu M, Vignon F, Capony F, Rochefort H. Estradiol downregulates the mannose-6-phosphate/IGFII receptor gene and induces cathepsin D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal pro-enzymes. Mol Endocrinol 1991; 5:815–822
Smith C. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 1998; 58:627–632
Aronica S, Katzenellenbogen B. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin growth factor-I. Mol. Endocrinol. 1993; 7:743–752
Lee A, Weng C, Jackson J, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J. Endocrinol. 1997; 152:39–47
Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol Chem. 1996; 271:1016–1021
Perlino E, Tommasi S, Moro L, Bellizzi A, Ersilia M, Casavola V, Reshkin S. TGF-β1 and IGF-I expression are differentially regulated by serum in metastatic and non-metastatic human breast cancer cells. Int. J. Oncol. 2000; 16:155–160
Ford C, Skiba N, Bae H, Daaka Y, Reuveny E, Shekter L, Rosal R, Weng G, Yang C, Iyengar R, Miller R, Jan L, Lefkowitz R, Hamm H. Molecular basis for interactions of G protein betagamma subunits with effectors. Science 1998; 280:1271–1274
Aral H, Tsou C, Charo I. Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B: Evidence that directed migration is mediated by βγ dimers released by activation of Gai-coupled receptors. Proc. Natl. Acad. Sci. USA 1997; 94:14495–14499
Neptune E, Bourne H. Receptors induce chemotaxis by releasing the βγ subunit of Gi, not by activating Gq or Gs. Proc. Natl. Acad. Sci. USA 1997; 94:14489–14494
Neptune E, Iiri T, Bourne H. Gαi is not required for chemotaxis mediated by Gi-coupled receptors. J. Biol. Chem. 1999; 274:2824–2828
Linseman D, Benjamin C, Jones D. Convergence of angiotensin II and the platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J. Biol. Chem. 1995; 270:12563–12568
Daub H, Weiss F, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379:557–560
Rao G, Delafontaine P, Runge M. Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1 and phospholipase C-gamma 2 in rat aortic smooth muscle cells. J. Biol. Chem. 1995; 270:27871–27875
Luttrell L, van Biesen T, Hawes B, Koch W, Touhara K, Lefkowitz R. G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J. Biol. Chem. 1995; 270:16495–16498
Kanzaki M, Nie L, Shibata H, Kojima I. Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I. J. Biol. Chem. 1997; 272:4964–4969
Uehara T, Tokumitsu Y, Nomura Y. Pertussis toxin-sensitive and insensitive intracellular signalling pathways in undifferentiated 3T3-L1 cells stimulated by insulin converge with phosphatidylinositol 3-kinase upstream of the Ras mitogen-activated protein kinase cascade. Eur. J. Biochem. 1999; 259:801–808
Stracke M, Engel J, Wilson L, Rechler M, Liotta L, Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J. Biol. Chem. 1989; 264:21544–21549
Langlois D, Hinsch K, Saez J, Begeot M. Stimulatory effect of insulin and insulin-like growth factor I on Gi proteins and angiotensin-II-induced phosphoinositide breakdown in cultured bovine adrenal cells. Endocrinology 1990; 126:1867–1872
Siebler T, Kiess W, Linder B, Kessler U, Schwarz H, Nissley S. Pertussis toxin sensitive G-proteins are not involved in the mitogenic signaling pathway of insulin-like growth factor-I in normal rat kidney epithelial (NRKE) cells. Regul. Pept. 1996; 62:65–71
Clapham D, Neer E. G protein beta gamma subunits. Annu. Rev. Pharmacol. Toxicol. 1997; 37:167–203
Sánchez-Margalet V, González-Yanes C, Santos-Alvarez J, Najib S. Insulin activates Gαi 1, 2 protein in rat hepatoma (HTC) cell membranes. Cell Mol. Life Sci. 1999; 55:142–147
Hallak H, Seiler A, Green J, Ross B, Rubin R. Association of heterotrimeric Gi with the insulin-like growth factor-I receptor. Release of Gβγ subunits upon receptor activation. J. Biol. Chem. 2000; 275:2255–2258
Mira E, Lacalle R, González M, Gómez-Moutón C, Abad J, Bernad A, Martínez-A C, Mañes S. A role for chemokine receptor transactivation in growth factor signaling. (Submitted for publication)
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptorsrequires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884–888
Ward S, Bacon K, Westwick J. Chemokines and T lymphocytes: more than attraction. Immunity 1998; 9:1–11
Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumourigenesis. J. Exp. Med. 1999; 190:1367–1370
Mack M, Luckow B, Nelson P, Cihak J, Simmons G, Clapham P, Signoret N, Marsh M, Strangassinger M, Borlat F, Wells T, Schlöndorff D, Proudfoot A. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 1998; 187: 1215–1224
Simmons G, Clapham P, Picard L, Offord R, Rosenkilde M, Schwartz T, Buser R, Wells T, Proudfoot A. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276:276–279
Liu R, Paxton W, Choe S, Ceradini D, Martin S, Horuk R, MacDonald M, Stuhlmann H, Koup R, Landau N. Homozygous defect in HIV-1 coreceptor accounts for resistence of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367–377
Samson M, Libert F, Doranz B, Rucker J, Liesnard C, Farber C, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth R, Collman R, Doms R, Vassart G, Parmentier M. Resistence to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996; 382:722–725
Benkirane M, Jin D, Chun R, Koup R, Jeang K. Mechanism of transdominant inhibition of CCR5-mediatedHIV-1 infection by cer5Δ32. Biol. Chem. 1997; 272:30603–30606
Sgroi D, Teng S, Robinson G, LeVangie R, Hudson J, Jr, Elkahloun A. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 1999; 59:5656–5661
Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999; 59:4681–4687
Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94:353–362
Quigley J, Armstrong P. Tumour cell intravasation Alu-cidated: the chick embryo opens the window. Cell 1998; 94:281–284
Mañes S, Llorente M, Lacalle RA, Gómez-Mouton C, Kremer L, Mira E, Martínez-A. C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J.Biol. Chem. 1999; 274:6935–6945
Krontiris T, Cooper G. Transforming activity of human tumour DNAs. Proc. Natl. Acad. Sci. USA 1981; 78:1181–1184
Pulciani S, Santos E, Lauver A, Long L, Robbins K, Barbacid M. Oncogenesin human tumour cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc. Natl. Acad. Sci. USA 1982; 79:2845–2549
Santos E, Tronick S, Aaronson S, Pulciani S, Barbacid M. T24 human bladder carcinoma oncogens is an activated form of the normal human homologue of BALB-and Harvey-MSV transforming genes. Nature 1982; 298:343–347
Harada S, Nishimoto I. Possible requirement of serum progression factors for transformation of BALB/c 3T3 fibroblasts byv-ras p21. FEBS Lett. 1991; 295:59–62
Falco J, Taylor W, Di Fiore P, Weissman B, Aaronson S. Interactions of growth factors and retroviral oncogenes with mitogenic signal transduction pathways of Balb/MK keratinocytes. Oncogene 1988; 2:573–578
Lemoni N, Mayall E, Wyllie F, Williams D, Goyns M, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumourigenesis. Oncogene 1989; 4:159–164
Bond J, Wyllie F, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstitution of tumour initiation in a human epithelium. Oncogene 1994; 9:281–290
Thomas G, Williams D, Williams E. Reversibility of the malignant phenotype in monoclonal tumours in the mouse. Br. J. Cancer 1991; 63:213–216
Kaleko M, Rutter W, Miller A. Overexpression of the human insulin-like growth factor I receptor promotes ligand dependent neoplastic transformation. Mol. Cell. Biol. 1990; 10:464–473
Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R. Effect of an u l lmutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 1994; 14:3604–3612
Morrione A, DeAngelis T, Baserga R. Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. J. Virol. 1995; 69:5300–5303
Coppola D, Ferber A, Miura M, Sell C, D’Ambrosio C, Rubin R, Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol. 1994; 14:4588–4595
Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumourogenesis. Nature 1994; 369:414–417
Trojan J, Blossey B, Johnson T, Rudin S, Tykocinski M, Ilan J, Ilan J. Loss of tumourigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. U.S.A. 1992; 89:4874–4878
Trojan J, Johnson T, Rudin S, Blossey B, Kelley K, Shevelev A, Abdul-Karim F, Anthony D, Tykocinski M, Ilan J, Ilan J. Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and-II in immunogenicity and differentiation. Proc. Natl. Acad. U.S.A. 1994; 91:6088–6092
Shapiro D, Jones B, Shapiro L, Dias P, Houghton P. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Invest. 1994; 94:1235–1242
Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumourigenic and induce regression of wild-type tumours. Cancer Res. 1994; 54:2218–2222
Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994; 54:4848–4850
Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman H, Kajstura J, Rubin R, Zoltick P, Baserga R. The insulin-like growth factor I receptor protects tumour cells from apoptosis in vivo. Cancer Res. 1995; 55:2463–2469
Lee C, Wu S, Gabrivolich D, Chen H, Nadaf-Rahrov S, Ciernick I, Carbone D. Antitumour effects of an adenovirus expressing antisense insulin-like growth I receptor on human lung cancer cell lines. Cancer Res. 1996; 56:3038–3041
Burfein P, Chernicky C, Rininsland F, Ilan J, Ilan J. Antisense RNA to type I insulin-like growth factor receptor suppresses tumour growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 1996; 93:7263–7268
Baserga R. The insulin-like growth factor I receptor: A key to tumour growth? Cancer Res. 1995; 55:249–252
Arteaga C, Kitten L, Coronado E, Jacobs S, Kull F, Allred D, Osborne C. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cell in athymic mice. J. Clin. Invest. 1989; 84:1418–1423
Arteaga C. Intereference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat. 1992; 22:101–106
Prager D, Li HL, Asa H, Melmed S. Dominant negative inhibition of tumourigenesis in vivo by human insulin-like growth factor-I receptor mutant. Proc. Natl. Acad. Sci. USA 1994; 91:2181–2185
Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab. Invest. 1993; 69:756–760
Chernicky C, Yi L, Tan H, Gan S, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumourigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000; 7:384–395
Long L, Rubin r, Baserga R, Brodt P. Loss of metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995; 55:1006–1009
Dunn S, M E, Sharp N, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett J. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998; 58:3353–3361
Tartare S, Mothe I, Kowalski-Chauvel A, Breittmayer J-P, Ballotti R, Van Obberghen E. Signal transduction by a chimeric insulin-like growth factor-1 (IGF-1) receptor having the carboxyl-terminal domain of the insulin receptor. J. Biol. Chem. 1994; 269:11449–11455
Kato H, Faria T, Stannard B, Roberts C, LeRoith D. Essential role of tyrosine residues 1131, 1135 and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol. Endocrinol. 1994; 8:40–50
Li S, Ferber A, Miura M, Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor receptor with mutations in the tyrosine kinase domain. J. Biol. Chem. 1994; 269:32558–32564
O’Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan G, Baserga R, Blattler W. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell Biol. 1997; 17:427–435
Surmacz E, Sell C, Swantek J, Kato H, Roberts C, LeRoith D, Baserga R. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp. Cell Res. 1995; 218:370–380
Miura M, Surmacz E, Burgaud J, Baserga R. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J. Biol. Chem. 1995; 270:22639–22644
Li S, Resnicoff M, Baserga R. Effect of mutations at serines 1280–1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J. Biol. Chem. 1996; 271:12254–12260
Peterson J, Jelinek T, Kaleko M, Siddle K, Weber M. Phosphorylation and activation of the IGF-I receptor in src-transformed cells. J. Biol. Chem. 1994; 269:27315–27321
Baserga R. Oncogenes and the strategy of growth factors. Cell 1994; 79:927–930
Lu K, Campisi J. Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts. Proc. Natl. Acad. Sci. USA 1992; 89:3889–3893
Dawson T, Radulescu A, Wynford-Thomas D. Expression of mutant p21 ras induces insulin-like growth factor 1 secretion in thyroid epithelial cells. Cancer Res. 1995; 55:915–920
Porras A, Hernandez E, Benito M. Ras proteins mediate induction of uncoupling protein, IGF-I, and IGF-I receptor in rat fetal brown adipocyte cell lines. DNA Cell Biol. 1996; 15:921–928
Porcu P, Ferber A, Pietrzkowski Z, Roberts C, Adamo M, LeRoith D, Baserga R. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulin-like growth factor 1 with its receptor. Mol. Cell. Biol. 1992; 12:3883–3889
Travali S, Reiss K, Ferber A, Petralia S, Mercer W, Calabreta B, Baserga R. Constitutively expressed c-myb abrogates the requirement for insulin-like growth factor 1 in 3T3 fibroblasts. Mol. Cell. Biol. 1991; 11:731–736
Werner H, Shen-Orr Z, Rauscher III F, Morris J, Roberts C, LeRoith D. Inhibition of cellular proliferation by the Wilms’ tumour suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol. Cell. Biol. 1995; 15:3516–3522
Werner H, Hernandex-Sanchez C, Karneili E, LeRoith D. The regulation of IGF-1 receptor gene expression. Int. J. Biochem. Cell Biol. 1995; 27:987–994
Werner H, Karnieli E, Rauscher III F, Roberts C, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U.S.A. 1996; 93:8318–8323
Zhang L, Kashanchi F, Zhan Q, Brady J, Fornace A, Seth P, Helman L. Regulation of insulin-like growth factor II P3 promoter by p53: A potential mechanism for tumourigenesis. Cancer Res. 1996; 56:1367–1373
Hartman A, Blaszyk H, Kovach J, Sommer S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends in Genetics 1997; 13:27–33
Daughaday W, Deuel T. Tumour secretion of growth factors. Endocrinol. Metab. Clin. N. Am 1991; 20:539–563
Zapf J, Futo E, Peter M, Froesch E. Can “big” insulin-like growth factor II in serum of tumour patients account for the development of extrapancreatic tumour hypoglycemia. J. Clin. Invest. 1992; 90:2574–2584
Baxter R, Daughaday W. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumours. J. Clin. Endocrinol. Metab. 1991; 73:696–702
DeSouza A, Hankins G, Washington M, Fine R, Orton T, Jirtle R. Frequent lost of heterozygosity on 6q at the mannose-6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumours. Oncogene 1995; 10:1725–1729
Lemamy G, Roger P, mani J, Robert M, Rochefort H, Brouillet J. High-affinity antibodies from hen’s-egg yolks against human mannose-6-phosphate/insulin-like growth-factor-II receptor (M6P/IGFII-R): characterization and potential use in clinical cancer studies. Int. J. Cancer 1999; 80:896–902
O’Gorman D, Costello M, Weiss J, Firth S, Scott C. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumourigenicity in JEG-3 cells. Cancer Res. 1999; 59:5692–5694
Oates A, Schumaker L, Jenkins S, Pearce A, DaCosta S, Arun B, MJ E. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumour suppresor gene. Breast Cancer Res Treat 1998; 47:269–281
D’Ercole A, Stiles A, Underwood L. Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanism of action. Proc. Natl. Acad. Sci. U.S.A. 1984; 81:935–939
Quinn K, Treston A, Unsworth E, Miller M-J, Vos M, Grimley C, Battey J, Mulshine J, Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J. Biol. Chem. 1996; 271:11477–11483
Macaulay V, Everard MJ, Teale JD, Trott PA, Van Wyk JJ, Smith IE, Millar JL. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumour cells. Cancer Res. 1990; 50:2511–2517
Bennington J, Strathearn M, Williams R, Spencer E. “Autocrine stimulation by IGF-I of renal cell carcinoma growth in vitro.” In Modern concepts of Insulin-like Growth Factors, E. Spencer, Ed. New York, Elsevier Science Publishing Co. Inc., 1991
Macaulay VM. Insulin-like growth factors and cancer. Br. J. Cancer 1992; 65:311–320
Lu K, Levine R, Campisi J. c-ras-Ha gene expression is regulated by insulin or insulin-like growth factor and by epidermal growth factor in murine fibroblasts. Mol. Cell. Biol. 1989; 9:3411–3417
Gebauer G, Jager W, Lang N. mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res. 1998; 18:1191–1195
Rasmussen A, Cullen, KJ. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res. Treat 1998; 47:219–233
Dunn S, Hardman R, Kari F, Barrett J. Insulin-like growth factor-I alters drug sensitivity of human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57:6795–6797
Trojan J, Johnson T, Rudin S, Ilan J, Tykocinski M, Ilan J. Treatment and prevention of rat glioblastoma by immunizing C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259:94–96
Baserga R, Resnicoff M, D’Ambrosio C, Valentinis B. The role of the IGF-I receptor in apopotosis. Vit. Horm. 1997; 53:65–98
Dawson T, Wynford-Thomas D. Does autocrine growth factor secretion form part of a mechanism which paradoxically protects against tumour development? Br. J. Cancer 1995; 71:1136–1141
Yang X, Beamer W, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in host homozygous for the lit mutation. Cancer Res. 1996; 56:1509–1511
Rogler C, Yang D, L R, Donohoe J, Alt E, Chand C, Rosenfeld R, Neely K, Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. Biol. Chem. 1994; 269:13779–13784
Bates P, Fisher R, Ward A, Richardson L, Hill D, Graham C. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer 1995; 72:1189–1193
DiGiovanni J, Bol D, Wilker E, Beltrán L, Carbajal S, Moats S, Ramirea A, Jorcano J, Kiguchi K. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumour promotion. Cancer Res 2000; 60:1561–1570
Bengtsson B. Acromegaly and neoplasia. J. Pediatr. Endocr. 1993; 6:73–78
Hunter D, Willet W. Diet, body size and breast cancer. Epid. Rev. 1993; 15:110–132
Giovannucci E, Rimm E, Stampfer M, Colditz G, Willett W. Height, body weight, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1997; 6:557–563
Albanes D, Jones D, Schatzkin A, Micozzi M, Taylor P. Adult stature and risk of cancer. Cancer Res. 1988; 48:1658–1662
Leon D, Smith G, Shipley M, Strachan D. Adult height and mortality in London: early life, socioeconomic confounding, or shrinkage? J. Epidemiol. Community Health 1995;49: 5–9
Hankinson S, Willett W, Colditz G, Hunter D, Michaud D, Deroo B, Rosner B, speizer F, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393–1396
Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P, Hennekens C, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563–566
Rosen C. Serum insulin-like grwoth factors and insulin-like growth factor binding proteins: clinical implications. Clin. Chem. 1999; 45:1384–1390
Peyrat J, Bonneterre J, Hecquet B, Vennin P, Louchez M, Fournier C, Lefebvre J, Demaille A. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur. J. Cancer 1993; 29A:492–497
Giani C, Cullen K, Campani K, Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ and immunohistochemistry study. Breast Cancer Res. Treat. 1996; 41:43–50
Pollak M, Hankinson S, Deroo B, Michaud D, Willett W, Speizer F. Relationship of circulating insulin-like growth factor-I level to breast cancer risk. Proceedings of the Fourth International Symposium on Insulin-Like Growth Factors, Tokyo, Japan 1997
Giovannucci E. Insulin-like growth factor-I, binding protein-3 and risk of cancer. Horm. Res. 1999; 51:34–41
Ruan W, Catanese V, Wieczorek R, Feldman m, Kleinberg D. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995; 36:1296–1302
Toropainen E, Lipponen P, Syrjanen K. Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. Eur. J. Cancer 1995; 31A:1443–1448
Pollack M, Huynh H, Lefebvre S. Tamoxifen reduces serum insulin-like growth factor I. Breast Cancer Res. Treat. 1992; 22:91–100
Bhatavedar J, Patel D, Karelia N, Vora H, Ghosh N, Shah N, Balar D, Trivedi S. Tumour markers in patients with advanced breast cancer as prognosticators: A preliminary study. Breast Cancer Res. Treat. 1994; 30:293–297
Toropainen E, Lipponen P, Syrjanen K. Expression of insulin-like growth factor II in human breast cancer as related to establised prognostic factors and long-term prognosis. Anticancer Res. 1995; 15:2669–2674
Yee D, Sharma J, Hilsenbeck S. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J. Natl. Cancer Inst. 1994; 84:1785–1789
Bohlke K, Cramer D, Trichopoulos D, Mantzoros C. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998; 9:570–573
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diadamandis E. Insulin-like growth factor-binding protein-3 and breast cancer survival. Int. J. Cancer 1998; 79:624–628
Rocha R, Hilsenbeck S, Jackson J, Lee A, Figueroa J, Yee D. Insulin-like growth factor binding protein-3 (BP3) mRNA and protein expression are correlated in primary breast cancer tissue; higher levels are detected in tumours with poor prognostic features. J. Natl. Cancer Inst. 1996; 88:601–606
Rocha R, Hilsenbeck S, Jackson J, Van Den Berg C, Weng C-N, Lee A, Yec D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 1997; 3:103–109
Yu H, Diamandis E, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce CM. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res. Treat. 1996; 40:171–178
Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. Clin. Cancer Res. 1997; 4:1489–1497
Peyrat J-P, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulin-like growth factor I receptors in human breast cancer and their relationship to estradiol and progesterone receptors. Cancer Res. 1988; 48:6429–6433
Pekonen F, Partanen S, Makinen T, Rutanen E. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 1988; 48:1343–1347
Foekens J, Portengen H, Janssen M, Klijn J. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 1989; 63:2139–2147
Bonneterre J, Peyrat J, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res. 1990; 50:6931–6935
Papa V, Gliozzo B, Clark G, McGuire W, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine I, Pezzino V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993; 53:3736–3740
Peyrat J, Bonneterre J. Typel IGF receptor in human breast disease. Breast Cancer Res. Treat. 1992; 22:59–67
Railo M, Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-1 in breast cancer patients. Eur. J. Cancer 1994; 30A:307–311
Turner B, Haffty B, Narayanan L, Yuan J, Havre P, Gumbs A, Kaplan L, Burgaud J, Carter D, Baserga R, Glazer P. Insulin-like growth factor-1 receptor overexpression mediated cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57:3079–3083
LeRoith D, Werner H, Beitner-Johnson D, Roberts C. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995; 16:143–163
Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 1998; 152:63–70
Ellis M, Jenkins, S, Manfelt, J, Redington, ME, Taylor, M, Leek, R, Siddle, K and Harris, A. Insulin-like growth factors in human breast cancer. Breast Cancer Res. Treat. 1998; 52:175–184
Berns E, Klijn J, van Staveren I, Portengen H, Foekens J. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast cancer. Cancer Res. 1992; 52:1036–1039
Martin-Du Pan R. Are the hormones of youth carcinogenic? Ann Endocrinol (Paris) 1999; 60:392–397
Colletti R, Roberts J, Devlin J, Copeland K. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989; 49:1882–1884
Pollak M, Constantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulin like growth factor 1 levels in stage 1 breast cancer patients. J. Natl. Cancer Inst. 1990; 82:1693–1697
Friedl A, Jordan V, Pollak M. Suppression of serum IGF-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur. J. Cancer 1993; 29A:1368–1372
Tannenbaum G, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinol. 1992; 130:3395–3401
Huynh H, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res. 1993; 53:1727–1730
Pollak M. Endocrine effects of IGF-I on normal and and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment prevention. Breast Cancer Res. Treat. 1998; 47:209–217
Lippman S, Lotan R. Advances in the development of retinoids as chemopreventive agents. J. Nutr. 2000; 130:479S–482S
Yang L, Tin-U C, Wu K, Brown P. Role of retinoid receptors in the prevention and treatment of breast cancer. J. Mammary Gland Biol. Neoplasia 1999; 4:377–388
Gucev Z, Oh Y, Kelley K, Rosenfeld K. Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996; 56:1545–1550
Oh Y, Muller H, Ng L, Rosenfeld R. Transforming growth factor-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem. 1995; 270:13589–13592
Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J. Natl. Cancer Inst. 1997; 89:652–656
Pollak M. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion 1996; 57:29–33
Bontenbal M, Foekens J, Lamberts S, de Jong F, van Putten W, Braun H, Burghouts J, van der Linden G, Klijn J. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br. J. Cancer 1998; 77:115–122
Rischke H, Staib-Sebler E, Mose S, Adams S, Herrmann G, Bottcher H, M L. Metastatic breast carcinoma with neuroendocrine differentiation— its combined therapy with tamoxifen and the somatostatin analog octreotide. Dtsch. Med. Wochenschr. 1999; 124:182–186
Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somastatin analogue. Biochem. Biophys. Res. Comm. 1994; 203:253–259
Ingle J, Suman V, Kardinal C, Krook J, Mailliard J, Veeder M, Loprinzi C, Dalton R, Hartmann L, Conover C, Pollak M. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999; 85:1284–1292
Juul A. Determination of insulin-like growth factor-i in the monitoring of growth hormone treatment with respect to efficacy of treatment and side effects, should potential risks of cardiovascular disease and cancer be considered? Horm. Res. 1999; 51: 141–148
Shim MaC, P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm. Res. 1999; 51:42–51
Kohn E, Liotta L. Molecular insights into cancer invasion: Strategies for prevention and intervetion. Cancer Res. 1995; 55:1856–1862
Birchmeier W, Weidner K, Behrens J. Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells. J. Cell. Sci. 1993; 17:159–164
Lauffenburger D, Horwitz A. Cell migration: a physically integrated molecular process. Cell 1996; 84:359–369
Tapson V, Boni Schnetzler M, Pilch P, Center D, Berman J. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J. Clin. Invest. 1988; 82:950–957
Shoji S, Ertl R, Linder J, Koizumi S, Duckworth W, Rennard S. Bronchial epithelial cells respond to insulin and insulin-like growth factor-I as a chemoattractant. Am. J. Respir. Cell. Mol. Biol. 1990; 2:553–557
Grant M, Jerdan J, Merimee T. Insulin-like growth factor-I modulates endothelial cell chemotaxis. J. Clin. Endocrinol. Metab. 1987; 65:370–371
Jones J, Prevette T, Gockerman A, Clemmons D. Ligand ocupancy of the αvβ3 integrin is neccessary for smooth muscle cells to migrate in response to insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 1996; 93:2482–2487
Stracke M, Engel J, Wilson L, Rechler M, Liotta L, Schiffmann E. The type-1 insulin-like growth factor receptor is a motility receptor in human melanoma cells. J. Biol. Chem. 1989; 264:21554–21549
Doerr M, Jones J. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J. Biol. Chem. 1996; 271:2443–2447
Brooks P, Klemke R, Schön S, Lewis J, Schwartz M, Cheresh D. Insulin-like growth factor receptor cooperates with integrin αvβ5 to promote tumour cell dissemination in vivo. J. Clin. Invest. 1997; 99:1390–1398
Kadowaki T, Koyasu S, Nishida E, Sakai H, Takaku F, Yahara I, Kasuga M. Insulin-like growth factors, insulin, and epidermal growth factor cause rapid cytoskeletal reorganization in KB cells. Clarification of the roles of type I insulin-like growth factor receptors and insulin receptors. J. Biol. Chem. 1986; 261:16141–16147
Abercrombie M, Heaysman J, Pegrum S. The locomotion of fibroblasts in culture. II. “Ruffling”. Exp. Cell. Res. 1970; 60:437–444
Ridley A. Membrane ruffling and signal transduction. Bioessays 1994; 16:321–327
Williams M, Hughes P, O’Toole T, Ginsberg M. The inner world of cell adhesion: integrin cytoplasmic domains. Trends Cell Biol 1994; 4:109–112
Clark E, Brugge J. Integrins and signal transduction pathways: the road taken. Science 1995; 268:233–239
Yamada K, Geiger B. Molecular interactions in cell adhesion complexes. Curr. Opin. Cell Biol. 1997; 9:76–85
Schlaepfer D, Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell. Biol. 1998; 8:151–157
Zetter BR. Adhesion molecules in tumour metastasis. Semin. Cancer Biol. 1993; 4:219–229
Varner JA, Cheresh DA. Integrins and cancer. Curr. Opin. Cell Biol. 1996; 8:724–730
Marshall JF, Hart IR. The role of αv-integrins in tumour progression and metastasis. Semin. Cancer Biol. 1996; 7:129–138
Filardo E, Brooks P, Deming S, Damsky C, Cheresh D. Requeriment of the NPXY motif in the integrin β3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. Cell. Biol. 1995; 130:441–450
Klemke R, Yebra E, Bayna E, Cheresh D. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J. Cell Biol. 1994; 127:850–866
Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T, Aizawa S. Reduced cell motility and enhanced focal contact formation in cells from FAK-deficient mice. Nature 1995; 377:539–544
Leventhal P, Shelden E, Kim B, Feldman E. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J. Biol. Chem. 1997; 272:5214–5218
Freedman V, Shin S. Cellular tumourigenicity in nude mice: Correlation with cell growth in semisolid medium. Cell 1974; 3:355–359
Schwartz M. Integrins, oncogenes and anchorage independence. J. Cell Biol. 1997; 139:575–578
Keely P, Parise L, Juliano R. Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol 1998; 8:101–106
Khawaja A, Rodriguez-Viciana P, Wennstrom S, Warne P, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase-B/AKT cellular survival pathway. EMBO J. 1997; 16:2783–2793
Rodríguez-Viciana P, Warne P, Khawaja A, Marte B, Pappin D, Das P, Waterfield M, Ridley A, Downward J. Role of phosphoinositide 3-OH kinase in cell transformation and control of actin cytoskeleton by ras. Cell 1997; 89:457–467
Lin T, Chen Q, Howe A, Juliano R. Cell anchorage permits signal transduction between ras and its downstream kinases. J. Biol. Chem. 1997; 272:8849–8852
Baron V, Calléja V, Ferrari P, Alengrin F, Van Obberghen E. p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptor. J. Biol. Chem. 1998; 273:7162–7168
Mańes S, Mira E, Gómez-Mouton C, Zhao Z, Lacalle R, Martínez-A C. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol. Cel. Biol. 1999; 19:3125–3135
Giancotti F, Ruoslahti E. Integrin signaling. Science 1999; 285:1028–1032
Blakesley V, Koval A, Stannard B, Scrimgeour A, LeRoith D. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth. J. Biol. Chem. 1998; 273:18411–18422
Rodríguez-Fernandez J, Geiger B, Salomon D, Ben-Ze’ev A. Suppression of vinculin expression by antisense transfection confers changes in cell morphology, motility and anchorage-dependent growth of 3T3 cells. J. Cell Biol. 1993; 122:1285–1294
Westmeyer A, Ruhnau K, Wegner A, Jockusch B. Antibody mapping of functional domains in vinculin. EMBO J. 1990; 9:2071–2078
Hughes P, Renshaw M, Pfaff M, Forsyth J, Keivens V, Schwartz M, Ginsberg M. Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 1997; 88:521–530
Qi J, Ito N, Claesson-Welsh L. Tyrosine phosphatase SHP-2 is involved in regulation of platelet-derived growth factor-induced migration. J. Biol. Chem. 1999; 274:14455–14463
Yu D, Qu C, Henegariu O, Lu X, Feng G. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration and focal adhesion. J. Biol. Chem. 1998; 273:21125–21131
Schneller M, Vuori K, Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBOJ. 1997; 16:5600–5607
Parent C, Blacklock B, Froehlich W, Murphy D, Devreotes P. G protein signaling events are activated at the leading edge of chemotactic cells. Cell 1998; 95:81–91
Meili R, Ellsworth C, Lee S, Reddy T, Ma H, Firtel R. Chemoattractant-mediated transient activation and membrane localization of Akt/PKB is required for efficient chemotaxis to cAMP in Dictyostelium. EMBO J. 1999; 18:2092–2105
Schrick K, Garvik B, Hartwell L. Mating in Saccharomyces cerevisiae: the role of the pheromone signal transduction pathway in the chemotropic response to pheromone. Genetics 1997; 147:19–32
Zigmond S. Mechanisms of sensing chemical gradients by polymorphonuclear leukocytes. Nature 1974; 249:450–452
Sullivan S, Daukas G, Zigmond S. Asymmetric distribution of chemotactic peptide receptor on polymorphonuclear leukocytes. J. Cell Biol. 1984; 99:1461–1467
Lawson M, Maxfield P. Ca2+ and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. Nature 1995; 377:75–79
Schmidt C, Horwitz A, Lauffenburger D, Sheetz M. Integrin-cytoskeletal interactions in migrating fibroblasts are dynamic, asymmetric, and regulated. J. Cell Biol. 1993; 123:977–991
Walter R, Marasco W. Localization of chemotactic peptide receptors on rabbit neutrophils. Exp. Cell. Res. 1984; 154:613–618
Schmitt M, Bultmann B. Fluorescent chemotactic peptide as tools to identify the f-Met-Leu-Phe receptor on human granulocytes. Biochem. Soc. Trans. 1990; 18:219–222
McKay D, Kusel J, Wilkinson P. Studies of chemotactic factor-induced polarity in human neutrophils. Lipid mobility, receptor redistribution and the time-sequence of polarization. J. Cell Sci. 1991; 100:473–479
Nieto M, Frade J, Sancho D, Mellado M, Martínez-A. C, Sánchez-Madrid F. Polarization of chemokine receptors to the leading edge during lymphocyte chemotaxis. J. Exp. Med. 1997; 186:153–158
Vicente-Manzanares M, Montoya M, Mellado M, Frade J, del Pozo M, Nieto M, de Landazuri M, Martínez-A. C, Sanchez-Madrid F. The chemokine SDF-1 alpha triggers a chemotactic response and induces cell polarization in human B lymphocytes. Eur. J. Immunol. 1998; 28:2197–21207
Xiao Z, Zhang N, Murphy D, Devreotes P. Dynamic distribution of chemoattractant receptors in living cells during chemotaxis and persistent stimulation. J. Cell Biol. 1997; 139:365–374
Servant G, Weiner O, Neptune E, Sedat J, Bourne H. Dynamics of a chemoattractant receptor in living neutrophils during chemotaxis. Mol. Biol. Cell 1999; 10:1163–1178
Izzard C, Lochner L. Formation of cell-to-substrate contacts during fibroblast motility: an interference-reflexion study. J. Cell Sci. 1980; 42:81–116
Regen C, Horwitz A. Dynamics of beta 1 integrin-mediated adhesive contacts in motile fibroblasts. J. Cell Biol. 1992; 119:1347–59
Mañes S, Mira E, Gómez-Moutón C, Lacalle R, Keller P, Labrador J, Martínez-A C. Membrane raft microdomains mediate front-rear polarity in migrating cells. EMBO J. 1999; 18:6211–6220
Fambrough D, McClure K, Kazlauskas A, Lander E. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 1999; 97:727–741
Nieto M, Rodriguez-Fernandez J, Navarro F, Sancho D, Frade J, Mellado M, Martinez-A. C, Cabanas C, Sanchez-Madrid F. Signaling through CD43 induces natural killer cell activation, chemokine release, and PYK-2 activation. Blood 1999; 94:2767–2777
Gruss H, Scott C, Rollins B, Brach M, Herrmann F. Human fibroblasts express functional IL-2 receptors formed by the IL-2R alpha-and beta-chain subunits: association of IL-2 binding with secretion of the monocyte chemoattractant protein-1. J. Immunol. 1996; 157:851–857
Liotta L, Mandler R, Murano G, Katz D, Gordon R, Chiang P, Schiffmann E. Tumour cell autocrine motility factor. Proc. Natl. Acad. Sci. U.S.A. 1986; 83:3302–3306
Betsuyaku T, Liu F, Senior R, Haug J, Brown E, Jones S, Matsushima K, Link D. A functional granulocyte colony-stimulating factor receptor is required for normal chemoattractant-induced neutrophil activation. J. Clin. Inves. 1999; 103:825–832
Rodriguez-Boulan E, Nelson W. Morphogenesis of the polarized epithelial cell phenotype. Science 1989; 245:718–725
Dotti C, Simons K. Polarized sorting of viral glycoproteins to the axon and dendrites of hippocampal neurons in culture. Cell 1990; 62:63–72
Simons K, Wandinger-Ness A. Polarized sorting in epithelia. Cell 1990; 62:207–210
Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387:569–572
Ledesma M, Simons K, Dotti C. Neuronal polarity: Essential role of protein-lipid complexes in axonal sorting. Proc. Natl. Acad. Sci. U.S.A. 1998; 95:3966–3971
Ledesma M, Brügger B, Bünning C, Wieland F, Dotti C. Maturation of the axonal plasma membrane requires upregulation of sphingomyelin synthesis and formation of protein-lipid complexes. EMBO J. 1999; 18:1761–1771
Brown D, Rose J. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 1992; 68:533–544
Müsch A, Xu H, Shields D, Rodriguez-Boulan E. Transport of vesicular stomatitis virus to the cell surface is signal mediated in polarized and nonpolarized cells. J. Cell Biol. 1996; 133:543–558
Yoshimori T, Keller P, Roth M, Simons K. Different biosynthetic transport routes to the plasma membrane in BHK and CHO cells. J. Cell Biol. 1996; 133:247–256
Keller P, Simons K. Cholesterol is required for surface transport of influenza virus hemagglutinin. J. Cell Biol. 1998; 140:1357–1367
Friedrichson T, Kurzchalia T. Microdomains of GPI-anchored proteins in living cells revealed by cross linking. Nature 1998; 394:802–805
Varma R, Mayor S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 1998; 394:798–801
Montixi C, Langlet C, Bernard A, Thimonier J, Dubois C, Wurbel M, Chauvin J, Pierres M, He H. Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. EMBO J. 1998; 17:5334–5348
Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartimentalization is required for efficient T cell activation. Immunity 1998; 8:723–732
Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999; 283:680–682
Brückner K, Labrador J, Scheiffele P, Herb A, Seeburg P, Klein R. Ephrin B ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron 1999; 22:511–524
Keski-Oja J, Koli K, Lohi J, Laiho M. Growth factors in the regulation of plasminogen-plasmin system in tumour cells. Semin. Thromb. Hemost 1991; 17:231–239
Santamaría I, Velasco G, Cazorla M, Fueyo A, Campo E, López-Otín C. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res 1998; 58:1624–1630
Vizoso F, Sanchez L, Diez-Itza I, Merino A, López-Otín C. Pepisnogen C is a new prognostic marker in primary breast cancer. J. Clin. Oncol. 1995; 13:54–61
López-Otín C, Diamandis E. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr. Rev 1998; 19:365–396
Friedl P, Noble P, Walton P, Laird D, Chauvin P, Tabah R, Black M, Zanker K. Migration of coordinated cell clusters in mesenchymal and epithelial cancer explants in vitro. Cancer Res. 1995; 55:4557–4560
Friedl P, Zanker K, Brocker E. Cell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin function. Microsc. Res. Tech. 1998; 43:369–378
Iocono J, Krummel T, Keefer K, Allison G, Paul H. Repeated additions of hyaluronan alters granulation tissue deposition in sponge implants in mice. Wound Repair Regen. 1998; 6:442–448
Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992; 14:455–463
Basset P, Bellocq J, Wolf C, Stoll I, Hutin P, Limacher J, Podhajcer O, Chenard M, Rio M, Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348:699–704
Freije J, Díez-Itza I, Balbín M, Sánchez L, Blasco r, Tolivia J, López-Otín C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 1994; 269:16766–16773
Puente X, Pendas A, Llano E, Velasco G, López-Otín C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56:944–949
Birkedal-Hansen H. Proteolytic remodeling of extracelular matrix. Curr. Opin. Cell Biol. 1995; 7:728–735
Sternlicht M, Bissell M, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumour promoter. Oncogene 2000; 19:1102–1113
Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumour progression: the contribution of MMP-9. Invasion Metastasis 1994–95; 14:246–258
Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 1994; 91:4293–4297
Lee O, Bae S, Bae M, Lee Y, Moon E, Cha H, Knon Y, Kim K. Identification of angiogenic properties of insulin-like growth factor II in vitro angiogenesis models. Br. J. Cancer 2000; 82:385–391
Matrisian L. Metalloproteinases and their inhibitors in tissue remodeling. Trends Genet. 1990; 6:121–125
Martin D, Fowlkes J, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J. Cell Biol. 1999; 146:881–892
Liotta L, Steeg P, Stetler-Stevenson W. Cancer metastasis and angiogenesis. an imbalance of positive and negative regulation. Cell 1991; 64:327–336
Höyhtyä M, fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson W, Liotta L, Liang C-M. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic-tissues with monoclonal antibodies. Int. J. Cancer 1994; 56:500–505
Visscher D, Höyhtyä M, Ottosen S, Liang C-M, Sarkar F, Crissman J, Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumour recurrence. Int. J. Cancer 1994; 59:339–344
Corcoran M, Stetler-Stevenson W. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J. Biol. Chem 1995; 270:13453–13459
Huhtala P, Humphries MJ, McCarthy JB, Tremble PM, Werb Z, Damsky CH. Cooperative signalling by α3β1 and α4β1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J. Cell Biol. 1995; 129:867–879
Riikonen T, Westermarck J, Koivisto L, Broberg A, Kähäri V-M, Heino J. Integrin α2β1 is a positive regulator of collagenase (MMP-1) and collagen α1 (I) gene expression. J. Biol. Chem. 1995; 270:13548–13552
Bafetti LM, Young TN, Itoh Y, Stack MS. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J. Biol. Chem. 1998; 273:143–149
Imai K, Shikata H, Okada Y. Degradation of vitronectin by matrix metalloproteinases-1,-2,-3,-7 and-9. FEBS Letters 1995; 369:249–251
Look M, Foekens J. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 1999; 107:150–159
Guy C, Cardiff R, Muller W. Induction of mammary tumours by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatis disease. Mol Cell Biol 1992; 12:954–961
Bugge T, Lund L, Kombrinck K, Nielsen B, Holmbäck K, Drew A, Flick M, Witte D, Dano, K, Degen J. Reduced metastasis of mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16:3097–3104
Grondahl-Hansen J, Christensen I, Rosenquist C, Brunner N, Mouridsen H, Dano, K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carciomas are associated with poor prognosis. Cancer Res. 1993; 53:2513–2521
Grondahl-Hansen J, Peters H, van Putten W, Look M, Pappot H, Ronne E, Dano K, Klijn J, Brunner N, Foekens J. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res. 1995; 1:1079–1087
Vaupel P, Thews O, Kelleher D, Hoeckel M. Oxygenation of human tumours: Evaluation of tissue oxygen distribution in breast cancer by computerized O2 tension measurements. Cancer Res 1991; 51:3316–3322
Maity A, Solomon D. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp. Cell. Res. 2000; 255:250–257
Pyke c, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brünner N, Dano K. Receptor for urokinase is present in tumours-associated macrophages in ductal breast carcinoma. Cancer Res. 1993; 53:1911–1915
Nielsen B, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest. 1996; 74:168–177
Dunn S, Torres J, Nihei N, Barrett J. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol. Carcinog. 2000; 27:10–17
Ree A, Bjornland K, Brunner n, Johansen H, Pedersern K, Aasen A, Fodstad O. Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin. Exp. Metastasis 1998; 16:205–215
Loskutoff D, Curriden S, Hu G, Deng G. Regulation of cell adhesion by PAI-I. APMIS 1999; 107:54–61
Lah T, Kokalj-Kunovar M, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, Kastelic L, Babnik J, Golouh R, Turk V. Stefins amd lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer 1992; 50:36–44
Poole A, Tiltman J, Recklies A, Stoker T. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978; 273:545–547
De Leon D, Issa N, Nainani S, Asmerom Y. Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisense insulin-likegrowth factor II(IGF-II). Horm. Metab. Res. 1999;31:142–147
Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis. APMIS 1999; 107: 86–95
Frosch B, Berquin I, Emmert-Buck M, Moin K, Sloane B. Molecular regulation, membrane association and secretion of tumour cathepsin B. APMIS 1999;107:28–37
Griffiths J. Are cancer cells acidic? Br. J. Cancer 1991; 64:425–427
Folkman T. Tumour angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971; 285:1182–1186
Pluda J. Tumour-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol. 1997; 24:203–218
Holmgren L, O’Reilly M, Folkman J. Dormancy of micrometastases: balanced proliferation andapoptosis in the presence of angiogenesis suppression. Nat. Med. 1995; 1:117–118
Folkman J, Watson K, Ingber D, al e. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58–61
Schweigerer L, Neufeld G, Friedman J, ale. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987; 325:257–259
Hamada J, Cavanaugh P, Lotan O, al e. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for matastasis. Br. J. Cancer 1992; 66:349–354
O’Reilly M, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat. Med. 1996; 2:689–692
Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66:1095–1104
Jouanneau J, Moens G, Bourgeois Y, Poupon M, Thiery J. A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumour progression. Proc. Natl. Acad. Sci. USA 1994; 91:286–290
Folkman J. What is the evidence that tumours are angiogenesis dependent? J. Natl. Cancer Inst. 1990; 82:4–6
Weidner N, Semple J, Welch W, Folkman J. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991; 324:1–8
Maione T, Gray G, Petro J, Hunt A, Donner A, Bauer S, Carson H, Sharpe R. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247:77–79
Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagilin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555–557
Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 2000; 34:185–194
Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G, Cheresh D. Integrin alpha v beta 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157–1164
Rastinejad F, Polverini P, Bouck N. Regulation of the activity of a new inhibitor of angiogenesis bya cancer suppresor gene. Cell 1989;56:345–355
Dameron K, Volpert O, Tainsky M, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of throm bospondin-1. Science 1994; 265:1582–1584
O’Reilly M, Holmgren L, Shing Y, Cheng C, Rosenthal R, Moses M, Lane W, Cao Y, Sage E, Folkman J. Angiostatin. A novel angiogenesis inhibitor that mediates the suppresion of metastases by a Lewis lung carcinoma. Cell 1994; 79:315–328
van Meir E, Polverini P, Chazin V, Su Huang H, de Tribolet N, Cavenee W. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 1994; 8:171–176
Moulder J, Rockwell S. Hypoxic fractions of solid tumours: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 1984; 10:695–712
Brown J. The hypoxic cell: a target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999; 59:5863–5870
Shweiki D, Itin A, Soffer D, Keshet E. Vasculae endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature 1992; 359:843–845
Guillemin K, Krasnow M. The hypoxic response. Huffing and HIFing. Cell 1997; 89:9–12
Gleadle J, Ebert B, Firth J, Ratcliffe P. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am. J. Physiol. 1995; 268:C1362–C1368
Yan S, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J. Biol. Chem. 1995; 270:11463–11471
Karakurum M, Shreeniwas R, Chen J, Pinsky D, Yan S, Anderson M, Sunouchi K, Major J, Hamilton T, Kuwabara K. Hypoxic induction of onterleukin-8 gene expression in human endothelial cells. J. Clin. Invest. 1994; 93:1564–1570
Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky D, Lyn P, Leavy J, Witte L, Joseph-Silverstein J, Furie M, Torcia G, Cozzolino F, Kamada T, Stern D. Hypoxiamediated induction of acidic 7 basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1995; 92:4606–4610
Levy A, Levy N, Goldberg M. Posttranscriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 1996; 271:2746–2753
Zhang L, Zhou W, Velculescu V, Kern S, Hruban R, Hamilton S, Vogelstein B, Kinzler K. Gene expression profiles in normal and cancer cells. Science 1997; 276:1268–1272
Maxwell P, Dachs G, Gleadle J, Nicholls L, Harris A, Stratford I, Hankinson O, Pugh C, Ratcliffe P. Hypoxia-inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc. Natl. Acad. Sci. USA 1997; 94:8104–8109
Jiang B-H, Agani F, Passaniti A, Semenza G. vSrc induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumour progression. Cancer Res. 1997; 57:5328–5335
Tazuke S, Mazure N, Sugawara J, Carland G, Faessen G, Suen L-F, Irwin J, Powell D, Giaccia A, Giudice L. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc. Natl. Acad. Sci. USA 1998; 95:10118–10193
Kim K, Bae S, Lee O, Bae M, Lee M, Park B. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58:348–351
Tucci M, Nygard K, Tanswell B, Farber H, Hill D, Han V. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis in cultured vascular endothelial cells. J. Endocrinol. 1998; 157:13–24
Zhong H, Agani F, Baccala A, Laughner E, Rioseco-Camacho N, Isaacs W, Simons J, Semenza G. Increased expression of hypoxiainducible factor 1 α in rat and human prostate cancer. Cancer Res. 1998; 58:5280–5284
Feldser D, Agani F, Iyer N, Pak B, Ferreira G, Semenza G. Reciprocal positive regulation of hypoxia-inducible factor 1 α and insulin-like growth factor 2. Cancer Res. 1999; 59:3915–3918
Bae M, Lee M, Bae S, Lee O, Lee Y, Park B, Kim K. Insulin-like growth factor II (IGF-II) secreted form HepG2 human hepatocellular carcinoma cells shows angiogenic activity. Cancer Lett 1998; 128:41–46
Bae S-k, Bae M, Ahn M-Y, Son M, Lee Y, Bae M-K, Lee O-H, Park B, Kim K-W. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res. 1999; 59:5989–5994
Volpert O, Jackson D, Bouck N, Linzer D. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 1996; 137:3871–3876
Warren R, Yuan H, Matli M, Ferrara N, Donner D. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. 1996; 271:29483–29488
Bermont L, Lamielle F, Fauconnet S, Esumi H, Weisz A, Adessi G. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinma cells. Int. J. Cancer 2000; 85:117–123
Zelzer E, Levy Y, Kahana C, Shilo B-Z, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia inducible factor HIF-1α/ARNT. EMBO J. 1998; 17:5085–5094
Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk A, Ryan H, Johnson R, Jefferson A, Stokoe D, Giaccia A. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; 14:391–396
Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res. 1996; 2:821–826
Spratt J, Greenberg R, Heuser L. Geometry, growth rates, and duration of cancer and carcinoma in situ of the breast before detection and screening. Cancer Res. 1986; 46:970–974
Zhuang Z, Merino M, Chuaqui R, Liotta L, Emmert-Buck M. Identical allelic loss on chromosome 11p13 in microdissected in situ and invasive human breast cancer. Cancer Res. 1995;55:467–471
Marcelli M, Haidacher S, Plymate S, Birnbaum R. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995; 136:1040–1048
Lee A, Hilsenbeck S, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res. Treat. 1998; 47:295–302
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Kluwer Academic Publishers
About this chapter
Cite this chapter
Mira, E., Lacalle, R.A., Martínez-A, C., Mañes, S. (2001). Insulin-like Growth Factor Axis Elements in Breast Cancer Progression. In: Snyder, C.R., Jiang, W.G., Matsumoto, K., Nakamura, T. (eds) Growth Factors and their Receptors in Cancer Metastasis. Cancer Metastasis - Biology and Treatment, vol 2. Springer, Dordrecht. https://doi.org/10.1007/0-306-48399-8_7
Download citation
DOI: https://doi.org/10.1007/0-306-48399-8_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-7141-0
Online ISBN: 978-0-306-48399-8
eBook Packages: Springer Book Archive